Results 181 to 190 of about 145,724 (263)

Echocardiographic Global Longitudinal Strain and Myocardial Fibrosis in Patients with Left Ventricular Hypertrophy and Hypertrophic Cardiomyopathy. [PDF]

Biomedicines
Matla-Hajzyk M, Balys M, Olejnik A, Brzoska P, Haberka M.   +4 more
europepmc   +1 more source

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Iminostilbene, a Carbamazepine Intermediate, Alleviates Myocardial Fibrosis after Myocardial Infarction via Targeting Galectin3. [PDF]

ACS Pharmacol Transl Sci
Li N, Zhou J, Wang Z, Wang M, Tian Y, Sun G.   +5 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

CC Chemokines in Myocardial Fibrosis: Regulatory Networks of CCL17 and Emerging Therapeutic Implications. [PDF]

Int J Mol Sci
Cai W, Zhao J, Zhang Z.
europepmc   +1 more source

BRG1 exacerbates myocardial fibrosis after myocardial infarction by interacting with ZEB1. [PDF]

Front Pharmacol
Cui Y, Jin J, Cui Y, Ma Z, Tong T, Xiong L, Shen M, Zhao Y, Guo X, Liang W, Zhao H, Ban T, Huo R.   +12 more
europepmc   +1 more source

Syncing Health Timing: Exploring the Interplay of Circadian Rhythms, Obesity, and Cardiovascular Diseases

Food Safety and Health, EarlyView.
Circadian rhythm disruption impairs metabolic regulation, appetite control, and vascular function, promoting obesity and cardiovascular diseases. Evidence highlights a bidirectional relationship where metabolic disorders further disturb circadian timing.
Ghizal Fatima, István Dalmadi, Anna Jánosi, Krisztina Takács, Eszter Halmy   +4 more
wiley   +1 more source

Effect of Dapagliflozin on Myocardial Fibrosis After STEMI: A Double-Blind, Placebo-Controlled Randomized Trial. [PDF]

J Clin Med
Ortega-Paz L, Laudani C, Morr CI, Sionis A, Vidal-Cales P, Arevalos V, Andrea R, De Diego O, Ortega E, Jimenez-Trinidad FR, Dantas AP, Angiolillo DJ, Sabaté M, Ortiz-Pérez JT, Brugaletta S.   +14 more
europepmc   +1 more source

Myocardial fibrosis.

The Medical journal of Malaya, 2003
openaire   +3 more sources